TY  - JOUR
AU  - Cheteh, Emarndeena H
AU  - Augsten, Martin
AU  - Rundqvist, Helene
AU  - Bianchi, Julie
AU  - Sarne, Victoria
AU  - Egevad, Lars
AU  - Bykov, Vladimir Jn
AU  - Östman, Arne
AU  - Wiman, Klas G
TI  - Human cancer-associated fibroblasts enhance glutathione levels and antagonize drug-induced prostate cancer cell death.
JO  - Cell death & disease
VL  - 8
IS  - 6
SN  - 2041-4889
CY  - London [u.a.]
PB  - Nature Publishing Group
M1  - DKFZ-2017-01475
SP  - e2848 -
PY  - 2017
AB  - Drug resistance is a major problem in cancer therapy. A growing body of evidence demonstrates that the tumor microenvironment, including cancer-associated fibroblasts (CAFs), can modulate drug sensitivity in tumor cells. We examined the effect of primary human CAFs on p53 induction and cell viability in prostate cancer cells on treatment with chemotherapeutic drugs. Co-culture with prostate CAFs or CAF-conditioned medium attenuated DNA damage and the p53 response to chemotherapeutic drugs and enhanced prostate cancer cell survival. CAF-conditioned medium inhibited the accumulation of doxorubicin, but not taxol, in prostate cancer cells in a manner that was associated with increased cancer cell glutathione levels. A low molecular weight fraction (<3 kDa) of CAF-conditioned medium had the same effect. CAF-conditioned medium also inhibited induction of reactive oxygen species (ROS) in both doxorubicin- and taxol-treated cancer cells. Our findings suggest that CAFs can enhance drug resistance in cancer cells by inhibiting drug accumulation and counteracting drug-induced oxidative stress. This protective mechanism may represent a novel therapeutic target in cancer.
LB  - PUB:(DE-HGF)16
C6  - pmid:28569790
C2  - pmc:PMC5520886
DO  - DOI:10.1038/cddis.2017.225
UR  - https://inrepo02.dkfz.de/record/125342
ER  -